Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...